We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 6/1/2023

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

Published in Dermatology

Journal Scan / Research · March 21, 2023

Efficacy of Paroxetine in the Treatment of Patients With Refractory Erythema of Rosacea

Journal of the American Academy of Dermatology




This abstract is available on the publisher's site.

Access this abstract now   Full Text Available for ClinicalKey Subscribers

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Academy of Dermatology
Paroxetine is an effective treatment for refractory erythema of rosacea: primary results from the PRRERCT (Prospective Rosacea Refractory Erythema Randomized Clinical Trial)
J Am Acad Dermatol 2023 Feb 14;[EPub Ahead of Print], B Wang, Y Huang, Y Tang, Z Zhao, W Shi, D Jian, F Liu, Q Gao, P Wang, J Yang, L Li, H Xie, J Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading